Universal Health beats, reiterates 2026 guidance at low end amid de novo, policy headwinds

Universal Health Services beats Q3 with EPS $5.22, revenue $4.73B, reiterates 2026 guidance at low end amid de novo, policy headwinds

• Booked $26M reserve tied to tentative Cumberland Hospital legal settlement and highlighted uncertainty around Medicaid supplemental payments.
• Adjusted EPS fell 8% YoY and EBITDA declined despite solid acute and behavioral volume growth.
• Underlying Q3 EBITDA missed internal expectations due to slow de novo ramps and softer surgical volumes.
• 2026 guidance reiterated, but management now explicitly guides investors to the low end of prior ranges.
• 2027 setup: $175–$200M Medicaid supplemental cuts and exchange/work-requirement risks vs $80–$100M loss recovery.
• Q3 2026 net income totaled $308.7M, alongside the company's revenue and EPS beats.
• Acute same-facility admissions rose 4.9%, but surgical cases fell 0.7% as procedures shift out of hospitals.
• Behavioral same-facility revenue grew 4% with volumes and pricing each up 2.1%, but Laurel Ridge drags margins.
• Labor remains a tailwind, with wage inflation ~3–3.5% and contract labor sharply lower vs pandemic peaks.
• Talkspace integration on track, major revenue synergies expected to build over 12–24 months, not yet in numbers.
• Strong cash generation funded $242M Q3 buybacks, capex to fall toward $800M post current de novo wave.
• Main investor debate centers on 2027 policy headwinds, surgical mix pressure, and Talkspace synergy realization.
• Main concern: 2027 Medicaid/exchange headwinds and slower de novo ramp could pressure margins despite volume strength.
• Mixed quarter, driven by strong volumes and good cost control offset by de novo losses and surgical softness.

https://finviz.com/stock?t=UHS&p=d